The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism.
Extracellular nucleotides (e.g. ATP, UTP, ADP) are released by activated endothelium, leukocytes and platelets within the injured vasculature and bind specific cell-surface type-2 purinergic (P2) receptors. This process drives vascular inflammation and thrombosis within grafted organs. Importantly, there are also vascular ectonucleotidases i.e. ectoenzymes that hydrolyze extracellular nucleotides in the blood to generate nucleosides (viz. adenosine). Endothelial cell NTPDase1/CD39 has been shown to critically modulate levels of circulating nucleotides. This process tends to limit the activation of platelet and leukocyte expressed P2 receptors and also generates adenosine to reverse inflammatory events. This vascular protective CD39 activity is rapidly inhibited by oxidative reactions, such as is observed with liver ischemia reperfusion injury. In this review, we chiefly address the impact of these signaling cascades following liver transplantation. Interestingly, the hepatic vasculature, hepatocytes and all non-parenchymal cell types express several components co-ordinating the purinergic signaling response. With hepatic and vascular dysfunction, we note heightened P2- expression and alterations in ectonucleotidase expression and function that may predispose to progression of disease. In addition to documented impacts upon the vasculature during engraftment, extracellular nucleotides also have direct influences upon liver function and bile flow (both under physiological and pathological states). We have recently shown that alterations in purinergic signaling mediated by altered CD39 expression have major impacts upon hepatic metabolism, repair mechanisms, regeneration and associated immune responses. Future clinical applications in transplantation might involve new therapeutic modalities using soluble recombinant forms of CD39, altering expression of this ectonucleotidase by drugs and/or using small molecules to inhibit deleterious P2-mediated signaling while augmenting beneficial adenosine-mediated effects within the transplanted liver.
Beldi
Guido
G
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA 02215, USA.
Enjyoji
Keiichi
K
Wu
Yan
Y
Miller
Lindsay
L
Banz
Yara
Y
Sun
Xiaofeng
X
Robson
Simon C
SC
D000818:Animals; D015703:Antigens, CD / Q000096:biosynthesis; D001081:Apyrase / Q000096:biosynthesis; D001792:Blood Platelets / Q000378:metabolism; D005227:Fatty Acids / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D008099:Liver / Q000378:metabolism*; D016031:Liver Transplantation / Q000379:methods*; D008954:Models, Biological; D009708:Nucleotidases / Q000737:chemistry; D009711:Nucleotides / Q000737:chemistry; D011983:Receptors, Purinergic / Q000378:metabolism; D015398:Signal Transduction
D015703:Antigens, CD; D005227:Fatty Acids; D009711:Nucleotides; D011983:Receptors, Purinergic; D009708:Nucleotidases; D001081:Apyrase; C067869:CD39 antigen; D005947:Glucose